IMMUNO-ONCOLOGY PLATFORM
and Emerging Targets in Oncology
Current Treatment Landscape for Cancer
BiTE® Immuno-Oncology Platform
Investigational Targets with the BiTE® Platform in Hematologic Malignancies: Multiple Myeloma and B-Cell Maturation Antigen (BCMA)
Investigational Targets with the BiTE® Platform in Solid Malignancies: Prostate Cancer and Prostate-Specific Membrane Antigen (PSMA)
Additional Emerging Targets for Investigation With the BiTE® Immuno-Oncology Platform
Meet the Speaker
Ajai Chari, MD
Mount Sinai School of Medicine
Program Objectives
The design of the BiTE® technology1
The potential of the BiTE® platform to target a range of tumors2
The major milestones in cancer treatment3,4
The cancer treatment landscape and how it has evolved with immuno-oncology therapies5
References
- Yuraszeck T, Kasichayanula S, Benjamin JE. Translation and clinical development of bispecific T-cell engaging antibodies for cancer treatment. Clin Pharmacol Ther. 2017;101(5):634-645.
- Amgen pipeline. Amgen website. https://www.amgenpipeline.com/-/media/themes/amgen/amgenpipeline-com/amgenpipeline-com/pdf/amgen-pipeline-chart.pdf. Accessed October 17, 2019.
- Cancer progress timeline. ASCO website. https://www.asco.org/research-guidelines/cancer-progress-timeline. Accessed October 17, 2019.
- Timeline of progress in immunotherapy. CRI website. www.cancerresearch.org/immunotherapy/timeline-of-progress. Accessed October 17, 2019.
- Hoos A, Britten C. The immuno-oncology framework: Enabling a new era of cancer therapy. Oncoimmunology. 2012;1(3):334-339.
Dr. Chari did not accept an honorarium for this program.
Amgenoncology.com
© 2019-2020 Amgen Inc. All rights reserved. USA-OCF-80650 08/2020